Georgia's Online Cancer Information Center

Leukemia Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Leukemia
Cancer Type = Leukemia
There are currently 77 active Leukemia clinical trials in Georgia.
1.
(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis
Cancer Type
Leukemia
NCT ID
NCT04996875
Protocol IDs
CGT9486-20-201
2021-001010-10
NCI-2021-09477
2.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05186753
Protocol IDs
CGT9486-21-202
NCI-2022-01167
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Phase 1 Study of Engineered Donor Grafts (OrcaGraft/Orca-Q) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03802695
Protocol IDs
OGFT001-001
NCI-2019-01953
Treatment Sites (1)
4.
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type
Leukemia, Lymphoma
NCT ID
NCT03420183
Protocol IDs
CIRM-0001
NCI-2018-00270
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT02723994
Protocol IDs
INCB 18424-269
NCI-2016-01687
AALL1521
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
7.
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Cancer Type
Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT04035434
Protocol IDs
CRSP-ONC-001
NCI-2019-07066
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04404660
Protocol IDs
FELIX (AUTO1-AL1)
AUTO1-AL1
NCI-2020-04370
2019-001937-16
10.
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT03740529
Protocol IDs
LOXO-BTK-18001
NCI-2019-02015
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation
Cancer Type
Leukemia
NCT ID
NCT04065399
Protocol IDs
SNDX-5613-0700
NCI-2019-07963
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Leukemia, Neuroblastoma, Non-Hodgkin Lymphoma
NCT ID
NCT03236857
Protocol IDs
M13-833
NCI-2017-02027
2017-000439-14
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
13.
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04546399
Protocol IDs
AALL1821
AALL1821
NCI-2020-06813
Treatment Sites (1)
14.
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Cancer Type
Leukemia
NCT ID
NCT04293562
Protocol IDs
AAML1831
AAML1831
NCI-2020-00546
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
15.
NCORP Trial
A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT03914625
Protocol IDs
AALL1731
AALL1731
NCI-2019-02187
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
16.
Actuate 1901: 9-ING-41 in Myelofibrosis
Cancer Type
Leukemia
NCT ID
NCT04218071
Protocol IDs
1901
NCI-2020-01824
17.
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Cancer Type
Leukemia
NCT ID
NCT03935555
Protocol IDs
PU-H71-01-003
NCI-2019-03010
18.
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
Cancer Type
Leukemia
NCT ID
NCT04258943
Protocol IDs
AAML1921
NCI-2020-07372
NTR5501
ITCC-054
2015-002916-34
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
Cancer Care Delivery in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT03204916
Protocol IDs
ACCL16N1CD
NCI-2017-01053
ACCL16N1CD
COG-ACCL16N1CD
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
20.
Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05274763
Protocol IDs
EU5492-21
NCI-2022-00233
STUDY00003563
21.
Childhood Cancer Survivor Study
Cancer Type
Brain & Spinal Cord Tumor, Hodgkin Lymphoma, Leukemia, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Solid Tumor
NCT ID
NCT01120353
Protocol IDs
CCSS
U24CA055727
Treatment Sites (2)
22.
Cholecalciferol in Improving Survival in Patients with Newly Diagnosed Cancer with Vitamin D Insufficiency
Cancer Type
Hodgkin Lymphoma, Leukemia, Lymphoma
NCT ID
NCT01787409
Protocol IDs
LS1293
P30CA015083
NCI-2013-00037
Mod12-007862-13
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
25.
NCORP Trial
Connect® Myeloid Disease Registry
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT01688011
Protocol IDs
Connect® MDS/AML Registry
Treatment Sites (10)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
26.
Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03263091
Protocol IDs
FGCL-4592-082
NCI-2017-02071
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
27.
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
Cancer Type
Leukemia
NCT ID
NCT04511130
Protocol IDs
MRKR-19-401
NCI-2020-07647
29.
Evaluation of Human Immune Responses to Vaccination in Patients with Lymphoma
Cancer Type
Hematopoietic Malignancies, Leukemia, Non-Hodgkin Lymphoma
NCT ID
NCT03501576
Protocol IDs
Winship4236-17
NCI-2017-02313
IRB00101067
Treatment Sites (2)
31.
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Cancer Type
Cancer-Related Syndrome, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04904588
Protocol IDs
ACCESS
NCI-2021-06605
32.
Hu8F4 in Treating Patients with Advanced Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies, Leukemia
NCT ID
NCT02530034
Protocol IDs
2014-0057
NCI-2015-02131
P-TRP-2447-14
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
33.
Ibrutinib with or without Cirmtuzumab in Treating Patients with B-Cell Lymphoid Malignancies
Cancer Type
Leukemia
NCT ID
NCT03088878
Protocol IDs
170127
NCI-2018-01703
NCT03420183
34.
NCORP Trial
Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT03007147
Protocol IDs
AALL1631
AALL1631
NCI-2016-01588
AALL1631
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
36.
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients with Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT03739814
Protocol IDs
A041703
A041703
NCI-2018-02484
37.
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT03150693
Protocol IDs
A041501
A041501
NCI-2016-01981
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
38.
NCORP Trial
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Cancer Type
Leukemia, Testicular Cancer
NCT ID
NCT03959085
Protocol IDs
AALL1732
AALL1732
NCI-2019-02845
Treatment Sites (3)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
39.
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02981628
Protocol IDs
AALL1621
AALL1621
NCI-2016-01494
AALL1621
Treatment Sites (1)
40.
IO-202 as Monotherapy and IO-202 Plus Azacitidine in Patients in AML and CMML
Cancer Type
Leukemia
NCT ID
NCT04372433
Protocol IDs
IO-202-CL-001
NCI-2020-07121
41.
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04313881
Protocol IDs
5F9009
NCI-2020-03406
2020-004287-26
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
42.
Modified Chemotherapy Regimen and Gemtuzumab Ozogamicin for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Pediatric Patients
Cancer Type
Leukemia
NCT ID
NCT04326439
Protocol IDs
AflacLL1901
NCI-2019-07692
IRB00111627
43.
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04676087
Protocol IDs
WINSHIP5101-20
NCI-2020-06013
44.
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant
Cancer Type
Leukemia
NCT ID
NCT03779854
Protocol IDs
RG1003345
9880
NCI-2018-01752
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
45.
NCORP Trial
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type
Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Solid Tumor
NCT ID
NCT04314401
Protocol IDs
10323
10323
NCI-2020-00750
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
46.
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Cancer Type
Leukemia
NCT ID
NCT03825367
Protocol IDs
T2016-002
NCI-2019-06317
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
47.
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04623944
Protocol IDs
NKX101-101
NCI-2020-11394
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
48.
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Cancer Type
Leukemia
NCT ID
NCT04872478
Protocol IDs
2843-1003
NCI-2021-13604
50.
NCORP Trial
Project: Every Child for Younger Patients with Cancer
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Leukemia, Solid Tumor, Unknown Primary
NCT ID
NCT02402244
Protocol IDs
APEC14B1
NCI-2014-02057
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
52.
Ruxolitinib and Tyrosine Kinase Inhibitors for the Treatment of Recurrent Chronic Phase-Chronic Myeloid Leukemia
Cancer Type
Leukemia
NCT ID
NCT03610971
Protocol IDs
MCC-19660
NCI-2019-08022
HJKC3-0002
53.
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Cancer Type
Leukemia
NCT ID
NCT04279847
Protocol IDs
INCB 57643-103
NCI-2020-07097
54.
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients with Chronic Phase Chronic Myeloid Leukemia
Cancer Type
Leukemia
NCT ID
NCT03817398
Protocol IDs
AAML18P1
AAML18P1
NCI-2018-03439
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
55.
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03013998
Protocol IDs
BAML-16-001
NCI-2017-00278
Treatment Sites (1)
56.
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCT ID
NCT02303821
Protocol IDs
CFZ008
NCI-2014-02601
2014-001633-84
57.
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Cancer Type
Leukemia, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03486067
Protocol IDs
CC-93269-MM-001
NCI-2018-02280
2017-003448-19
U1111-1210-6325
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
58.
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Cancer Type
Leukemia
NCT ID
NCT03876769
Protocol IDs
CCTL019G2201J
NCI-2019-02353
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
59.
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Cancer Type
Leukemia
NCT ID
NCT04260022
Protocol IDs
HQP1351CU101
NCI-2020-01100
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
60.
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Cancer Type
Leukemia, Multiple Myeloma
NCT ID
NCT02952508
Protocol IDs
DCL-16-001
NCI-2017-01758
61.
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Cancer Type
Leukemia, Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm
NCT ID
NCT05024045
Protocol IDs
LOXO-BCL-20001
NCI-2021-10661
2021-000060-30
J3N-OX-JZRA
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
63.
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Cancer Type
Hematopoietic Malignancies, Leukemia
NCT ID
NCT02074839
Protocol IDs
AG120-C-001
NCI-2014-00720
65.
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04315324
Protocol IDs
S1905
S1905
NCI-2020-00768
66.
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04301076
Protocol IDs
10335
10335
NCI-2020-01535
67.
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04530565
Protocol IDs
EA9181
EA9181
NCI-2020-06381
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
68.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCT ID
NCT03805789
Protocol IDs
CSL964_2001
NCI-2019-03310
2018-000329-29
Treatment Sites (1)
69.
Therapeutic Immune Cells (Gamma-Primed Mesenchymal Stromal Cells) for the Prevention of Acute Graft versus Host Disease after Donor Stem Cell Transplant in Patients with Blood Cancers or Myelodysplastic Syndrome
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04328714
Protocol IDs
CHOA4439-18
NCI-2022-01159
70.
NCORP Trial
Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02775383
Protocol IDs
NHLBI-MDS
NCI-2016-00281
Treatment Sites (15)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
72.
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Cancer Type
Leukemia
NCT ID
NCT04551066
Protocol IDs
INCB 50465-313/LIMBER-313
NCI-2021-01110
INCB 50465-313
73.
Trametinib in Treating Patients with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT03190915
Protocol IDs
ADVL1521
ADVL1521
NCI-2017-00921
ADVL1521
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
74.
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT03786926
Protocol IDs
2018-689-US001
NCI-2019-01158
2018-689-00US1
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
75.
Vaccine Therapy in Treating Patients with Acute Myeloid Leukemia following Chemotherapy-Induced Remission
Cancer Type
Leukemia
NCT ID
NCT03059485
Protocol IDs
16-593
NCI-2017-01191
77.
Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCT ID
NCT03842696
Protocol IDs
UMCC 2018.081
NCI-2019-04695
HUM00147796
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.